A case for prodrugs: Fosphenytoin

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 311-330

  Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

ACC 9653, Cerebyx; Clinical usefulness; Pharmacokinetics; Phenytoin; Phosphate ester; Prodrug; Safety; Solubility; Stability

Indexed keywords

ACCIDENT PREVENTION; BIOSYNTHESIS; CRYSTALLIZATION; DRUG THERAPY; ESTERS; PH; PHARMACOKINETICS; PHOSPHATES; SODIUM COMPOUNDS; SOLUBILITY; STABILITY;

CLINICAL USEFULNESS; FOSPHENYTOIN; INTRAVENOUS ADMINISTRATION; PHENYTOIN; WATER SOLUBLE DRUG;

DRUG PRODUCTS;

FOSPHENYTOIN SODIUM; PRODRUG;

CRYSTALLIZATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

EID: 0342833001     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00112-K     Document Type: Review

References (115)

1. Varia, S.A., Schuller, S., Sloan, K.B. and Stella V.J. (1984) Phenytoin prodrugs. III: Water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73, 1068-1073.
2. Stella, V.J. (1984) Chemical and physical bases determining the instability and incompatibility of formulated injectable drugs. J. Parenter. Sci. Technol. 40, 142-163.
3. Newton, D.W. and Kluza, R.B. (1980) Prediction of phenytoin solubility in intravenous admixtures: Physicochemical theory. Am. J. Hosp. Pharm. 37, 1647-1651.
4. Schwartz, P.A., Rhodes, C.T. and Cooper, J.W. (1977) Solubility and ionization characteristics of phenytoin. J. Pharm. Sci. 66, 994-997.
5. a value for 5,5-diphenylhydantoin. J. Pharm. Sci. 57, 1434-1435.
6. Cloyd, J.C., Bosch, D.E. and Sawchuck, R.J. (1978) Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am. J. Hosp. Pharm. 35, 45-48.
7. Salem, R.B., Yost, R.L., Torosian, G., Davis, F.T. and Wilder, B.J. (1980) Investigation of the crystallization of phenytoin in normal saline. Drug Intell. Clin. Pharm. 14, 605-608.
8. Gatti, G., Perucca, E., Caravaggi, M., Poloni, M., Frigo, G.M. and Crema, A. (1977) Pharmacokinetics of phenytoin following intravenous administration in epileptic patients. Il Farm. 32, 470-474.
9. Kilarski, D.J., Buchanan, C. and Von Behren, L. (1984) Soft-tissue damage associated with intravenous phenytoin. New Engl. J. Med. 311, 1186-1187.
10. Atkinson Jr., A.J. and Davison, R. (1974) Diphenylhydantoin as an antiarrhythmic drug. Annu. Rev. Med. 25, 99-113.
11. Sciabine, A., Kostis, J., Bellet, S., Morgan, G. Jr. and Rival J. (1970) Some aspects of interaction between diphenylhydantoin and digoxin by simultaneous administration to dogs. Toxicol. Appl. Pharmacol. 17, 708-720.
12. Unger, A.H. and Sklaroff, H.J. (1967) Fatalities following intravenous use of sodium phenytoin for cardiac arrhythmias. J. Am. Med. Assoc. 200, 335-336.
13. Voigt, G.C. (1968) Death following intravenous sodium diphenylhydantoin (Dilantin). Johns Hopkins Med. J. 123, 153-157.
14. Zoneraich, S., Zoneraich, O. and Siegel, J. (1976) Sudden death following intravenous sodium diphenylhydantoin. Am. Heart J. 91, 375-377 and references therein.
15. Wilensky A.J. and Lowden, J.S. (1973) Inadequate serum levels after intramuscular administration of diphenylhydantoin. Neurology 23, 318-324.
16. Dam, M. and Olesen, V. (1966) Intramuscular administration of phenytoin. Neurology 16, 288-292.
17. Kostenbauder, H.B., Rapp, R.P., McGovren, J.P., Foster, T.S., Perrier, D.G. Balcker, H.M. Hulon, W.C. and Kinkel, A.W. (1975) Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin. Clin. Pharmacol. Ther. 18, 449-456.
18. Wilder B.J., Serrano, E.E., Ramsey, E. and Buchanan, R.A. (1974) A method for shifting from oral to intramuscular diphenylhydantoin administration. Clin. Pharmacol. Ther. 16, 507-513.
19. Bundgaard, H. and Johansen, M. (1980) Pro-drugs as drug delivery systems. XV. Bioreversible derivatization of phenytoin, acetazolamide, chloroxazone and various other NH-acidic compounds by N-aminomethylation to effect enhanced dissolution rates. Int. J. Pharm. 7, 129-136.
20. Ogiso, T., Iwaki, M., Tanino, T., Muraoka, O and Tanabe, G. (1993) Pharmacokinetic analysis of phenytoin and its derivatives in plasma and brain of rats. Biol. Pharm. Bull. 16, 1025-1030.
21. Umemoto, S. (1965) Synthesis and rearrangement of ethoxycarbonylhydantoin derivatives. Yakugaku Zasshi, 84, 504-508.
22. Nakamura, K., O'Hashi, K., Nakatsuji, K., Hirooka, T., Fujimoto, K and Ose, S. (1965) The anticonvulsant activity of 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) in animals. Arch. Int. Pharmacodyn. 156, 261-270.
23. Samour, C.M., Reinhard, J.F. and Vida, J.A. (1971) Anticonvulsants. 1. Alkoxymethyl derivatives of barbiturates and diphenylhydantoin. J. Med. Chem. 14, 187-189.
24. Vida, J.A., O'Dea, M.H. and Samour, C.M. (1975) Anticonvulsants. 5. Derivatives of 5-ethyl-5-phenylhydantoin and 5,5-diphenylhydantoin. J. Med. Chem. 18, 383-385.
25. Scriba, G.K.E. (1993) Phenytoin-lipid conjugates as potential prodrugs of phenytoin. Arch. Pharm. (Weinheim), 326, 477-481.
26. Scriba G.K.E., Lambert, D.M. and Poupaert, J.H. (1995) Anticonvulsant activity of phenytoin-lipid conjugates, a new class of phenytoin prodrugs. J. Pharm. Pharmacol. 47, 197-203.
27. Scriba G.K.E., Lambert, D.M. and Poupaert, J.H. (1995) Bioavailability and anticonvulsant activity of a monoglyceride-derived prodrug of phenytoin after oral administration to rats. J. Pharm. Sci. 84, 300-302.
28. Yamaoka, Y., Roberts, R.D. and Stella, V.J. (1983) Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin; A model for other high-melting sparingly water soluble drugs. J. Pharm. Sci. 72, 400-405.
29. Alvarez, F.J. and Stella, V.J. (1989) Pancreatic lipase-catalyzed hydrolysis of esters of hydroxymethyl phenytoin dissolved in various metabolizable vehicles, dispersed in micellar systems, and in aqueous suspensions. Pharm. Res. 6, 555-563.
30. Terada K., Martodihardjo, S., Fukuoka, E. and Stella, V.J. (1990) In vitro and in vivo behavior of phenytoin prodrugs. Rec. Dev. Pharm. Pharmacol. Technol. 164-173.
31. Stella, V. and Higuchi, T. (1973) Esters of hydantoic acids as prodrugs of hydantoins. J. Pharm. Sci. 62, 962-967.
32. Stella, V., Higuchi, T., Hussain, A. and Truelove, J. (1975) The chemistry of a novel 5,5-diphenylhydantoin pro-drug. In: T. Higuchi and V. Stella (Eds), Pro-Drugs Novel Drug Delivery Systems, American Chemical Society, Washington, DC, pp. 154-183.
33. Higuchi, T. and Stella, V.J. (1974) Esters of hydantoic acid. US Patent 3,792,081, February 12.
34. Glazko, A.J., Dill, W.A., Wheelock, R.H., Young, R.M., Nemanich, A., Croskey. L., Stella, V. and Higuchi, T. (1975) The metabolic disposition of a novel 5,5-diphenylhydantoin pro-drug. In: T. Higuchi and V. Stella (Eds), Pro-Drugs Novel Drug Delivery Systems, American Chemical Society, Washington, DC, pp. 184-195.
35. Varia, S.A., Schuller, S. and Stella, V.J. (1984) Phenytoin prodrugs. IV: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters. J. Pharm. Sci. 73, 1074-80.
36. Varia, S.A. and Stella, V.J. (1984) Phenytoin prodrugs V: In vivo evaluation of some water soluble phenytoin prodrugs in dogs. J. Pharm. Sci. 73, 1080-87.
37. Varia, S.A. and Stella, V.J. (1984) Phenytoin prodrugs. VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J. Pharm. Sci. 73, 1087-90.
38. Stella, V.J. and Sloan, K.B. (1979) Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and therapeutic use thereof. US Patent 4,163,058, July 31.
39. Stella, V.J. and Sloan, K.B (1981) 5,5-Diphenylhydantoins. US Patent 4,260,769, April 7.
40. Muller, D.G. and Stella, V.J. (1987) An analytical method to determine small quantities of phenytoin in the presence of excess amounts of one of its prodrugs, the monomethane sulphonate salt of 3-(N,N-dimethylglycyloxymethyl)-5,5-diphenylhydantoin. J. Pharm. Biomed. Anal. 5, 415-421.
41. Muller, D.G., Stella, V.J. and Lotter, A.P. (1991) Factors influencing the precipitation time of phenytoin in the presence of DDMS, one of its prodrugs. Int. J. Pharm. 75, 201-209.
42. Muller, D.G., Stella, V.J. and Lotter, A.P. (1992) The determination of the amphiphilic properties of a pro-drug (DDMS) of phenytoin in aqueous media. Int. J. Pharm. 86, 175-186.
43. Muller, D.G., Stella, V.J. and Lotter, A.P. (1994) Determination of the position of the ester bond in a micellar prodrug of phenytoin. Int. J. Pharm. 102, 109-116.
44. Dal Pozzo, A. and Acquasaliente, M. (1992) New highly water-soluble phenytoin prodrugs. Int. J. Pharm. 81, 263-265.
45. Martodihardjo, S. (1987) Low-melting phenytoin pro-drugs: In vitro and in vivo correlations. Ph.D. dissertation, University of Kansas.
46. Murakami, T., Shek, E., Pop, E. and Bodor, N. (1989) Improved anticonvulsant activity of phenytoin by a redox brain delivery system. II: stability of buffers and biological materials. J. Pharm. Sci. 78, 732-737.
47. Stella, V.J. and Myers, R.A. (1988) Evaluation of a cumulative time/temperature indicator system. J. Pharm. Technol. 12, 106-116.
48. Kearney, A.S. and Stella, V.J. (1993) Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: Correlation to an established structure-reactivity relationship. J. Pharm. Sci. 82, 69-72.
49. Herbranson, D. E., Speicher, E. R. and Rosenberg, L. S. (1990) Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester. US Patent 4,925,860, May 15.
50. Kearney, A. S. (1990) Evaluation of the pharmaceutical potential of phosphate monoester prodrugs. Ph.D. dissertation, University of Kansas.
51. Kearney, A.S. and Stella, V.J. (1992) The in vitro enzymatic labilities of chemically distinct phosphomonoesters prodrugs. Pharm. Res. 9, 497-503.
52. Quon, C.Y. and Stampfli, H.F. In vitro hydrolysis of ACC-9653 (phosphate ester prodrug of phenytoin) by human, dog, rat blood and tissues. Pharm. Res. 3, 134S (Abstr. 143).
53. Tenhoor, C.N. and Stewart, B.H. (1994) The stability of fosphenytoin (CI-982) in the presence of intestinal phosphatases. Pharm. Res. 11, S299 (Abstr. PDD 7499).
54. Lai, C.M., Moore, P., Matier, W.L. and Quon, C.Y. (1987) Comparative pharmacokinetics and bioavailability of phenytoin after oral phenytoin sodium capsule and IM injection and oral capsule of a prodrug of phenytoin, ACC-9653, in dogs. Pharm. Res. 2, S118 (Abstr. 758).
55. Lai, C.M., Moore, P., Matier, W.L. and Quon, C.Y. (1987) Bioequivalence of ACC-9653 (A), a phosphate ester prodrug of phenytoin, to phenytoin sodium (P-NA) after IV administration in dogs. Pharmacology 29, 143 (Abstr. 206)
56. Lai, C.M., Moore, P. and Matier, W.L. (1986) Pharmacokinetics and absolute bioavailability of a prodrug of phenytoin, ACC-9653, after IM administration in dogs. Acta Pharmacol. Toxicol. 59, 213 (Abstr. 1297).
57. Lai, C.M., Moore, P., Matier, W.L. and Quon, C.Y. (1987) Comparative pharmacokinetics and bioavailability of phenytoin (P) after oral phenytoin sodium capsule (P-NA) and IM injection of ACC-9653 (A), a prodrug of P, in dogs. Fed. Proc. 46, 867 (Abstr. 3212).
58. Chan, Y.C., Bavda, L.T., Bobadilla, L.C. and Quon, C.Y. (1988) Metabolism and disposition of 14-C-ACC-9653, 3-phosphoryloxymethyl-(4-14-C)-5,5-diphenylhydantoin, in rats. FASEB. J. 2, A1063 (Abstr. 4458).
59. Stampfli, H.F., Chan, Y.C., Bavda, L. and Quon, C.Y. (1994) Tissue distribution of fosphenytoin (CI-982) in rats. Pharm. Res. 11, S427 (Abstr. 8379).
60. Gerber, N., Mays, D.C., Donn, K.H., Laddu, A., Guthrie, R.M., Turlapaty, P., Quon, C.Y. and Rivenburg, W.K. (1988) Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J. Clin. Pharmacol. 28, 1023-1032.
61. Rivenburg, W., Gerber, N., Donn, K., Mays, D., Blanski, L. Turlapaty, P., Laddu, A. and Quon, C.Y. (1987) Pharmacokinetics and dose proportionality of ACC-9653, a prodrug of phenytoin in healthy volunteers. Fed. Proc. 46, 708 (Abstr. 2289).
62. Eldon, M.A., Loewen, G.R., Voigtman, R.E., Holmes, G.B., Hunt, T.L. and Sedman, A.J. (1993) Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin. Clin. Pharmacol. Ther. 53, 212 (Abstr. PIII-23).
63. Eldon, M.A. Loewen, G. R., Voigtman, R.E., Koup, J.R., Holmes, G.B., Hunt, T.L., Sedman, A.J. and Cook, J.A. (1993) Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to health subjects. Can. J. Neurol, Sci. 20, S180 (Abstr. 6-11-11).
64. Jamerson, B.D., Donn, K.H., Dukes, G.E., Messenheimer, J.A., Brouwer, K.L.R. and Powell, J.R. (1990) Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia 31, 592-597.
65. Browne, T.R., Davoudi, H., Donn, K. H., Dougherty, C.L., Dukes, G.E., Evans, B., Evans, J.E., Jamerson, B., Kres, J., McEntegart, C.M., Messenheimer, J.A. Jr., Powell, J.R., Quon, C.Y. and Szabo, G.K. (1989) Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia 30, S27-S32.
66. Browne, T.R., Szabo, G.K., McEntegart, C., Evans, J.E., Evans, B. A., Quon, C., Dougherty, C.L., Kres, J. and Davoudi, H. (1990) Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentration determined by double stable isotope technique. J. Clin. Pharmacol. 30, 837 (Abstr. 26).
67. Browne, T.R., Miceli, J., Szabo, G.K., McEntegart, C., Evans, J.E., Evans, B. A., Quon, C., Dougherty, C.L., Kres, J. and Davoudi, H. (1991) Pharmacokinetics of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double stable isotope technique. Neurology 41, 138 (Abstr. 90P).
68. Browne, T.R., Szabo, G.K., McEntegart, C., Evans, J.E., Evans, B.A., Miceli, J.J., Quon, C., Dougherty, C.L., Kres, J. and Davoudi, H. (1993) Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin serum concentrations determined by double-stable isotope technique. J. Clin. Pharmacol. 33, 89-94.
69. Browne, T.R. and Szabo, G.K. (1991) New pharmacokinetic methods for the study of antiepileptic medications of the 1990s. Epilepsia 32, S66-S73.
70. Leppik, I.E., Boucher, R., Wilder, B.J., Murthy, V.S., Rask, C.A., Watridge, C., Graves, N.M., Rangel, R.J. and Turlapaty, P. (1989) Phenytoin prodrug: Preclinical and clinical studies. Epilepsia 30, S22-S26.
71. Leppik, I.E., Boucher, B.A., Wilder, B.J., Murthy, V.S., Watridge, C., Graves, N.M., Rangel, R.J., Rask, C.A. and Turlapaty, P. (1990) Pharmacokinetics and safety of phenytoin prodrug given IV or IM in patients. Neurology 40, 456-460.
72. Boucher, B.A., Bombassaro, A.M., Rasmussen, S.N., Watridge, C.B., Achari, R. and Turlapaty, P. (1989) Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): Pharmacokinetics in patients following intravenous and intramuscular administration. J. Pharm. Sci. 78, 929-932.
73. Aweeka, F., Alldredge, B., Boyer, T., Warnock, D. and Gambertoglio, J. (1989) Conversion of ACC-9653 to phenytoin in patients with renal or hepatic diseases. Clin. Pharmacol. Ther. 45, 152 (Ahstr. PIIK-2).
74. Smith, R.D., Brown, B.S., Maher, R.W. and Matier, W.L. (1989) Pharmacology of ACC-9653 (phenytoin prodrug). Epilepsia 30, S15-S21.
75. Walton, N.Y. and Treiman, D.M. (1989) Comparison of ACC-9653 and standard phenytoin in treatment of experimental status epilepticus. Epilepsia 30, 714-715.
76. Walton, N.Y. and Treiman, D.M. (1990) Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res. 5, 165-168.
77. Hussey, E.K., Dukes, G.E., Messenheimer, J.A., Brouwer, K.L.R., Donn, K.H., Krol, T.F. and Hak, L.J. (1988) Protein binding of phenytoin (DPH) and a DPH prodrug (PD). Pharm. Res. 5, S-214 (Abstr. 1463).
78. Hussey, E.K., Dukes, G.E., Messenheimer, J.A., Brouwer, K.L.R., Donn, K.H., Krol, T.F. and Hak, L.J. (1989) Protein binding of phenytoin and a phenytoin prodrug. Pharmacotherapy 9, 196-196 (Abstr. 152E).
79. Hale, V.G., Kaus, L.C., Eldon, M.A. and Olson, S.C. (1994) Exploratory simulations of the influence of dose and rate on phenytoin concentrations. Pharm. Res. 11, S421 (Abstr. 8354).
80. Kugler, A.R., Olson, S.C., Webb, C.L., Annesley, T., Nordblom, G.D. and Koup, J.R. (1994) Cross-reactivity of fosphenytoin (Cerebyx) in 2 human phenytoin immunoassays. Pharm. Res. 11, S102 (Abstr. 3015).
81. Hussey, E.K., Dukes, G.E., Messenheimer, J.A., Brouwer, K.L.R., Donn, K.H., Krol, T.F. and Hak, L.J. (1990) Evaluation of the pharmacokinetic interaction between diazepam and AC-9653 (a phenytoin prodrug) in healthy male volunteers. Pharm. Res. 7, 1172-1176.
82. Boxer, P.A., Cordon, J.J. and Marcoux, F.W. (1991) Fosphenytoin, a prodrug of phenytoin, reduces infarct size in a rat focal ischemia model. Stroke 22, 141 (Abstr. 61).
83. Cordon, J.J., Boxer, P.A. and Marcoux, F.W. (1991) The effects of fosphenytoin on infarct size and behavioral deficit in rat models of focal ischemia. Soc. Neurosci. Abstr. 17 (Pt 2), 1078 (Abstr. 425.6).
84. Boxer, P.A. and Wallace, J.D. Use of prophenytoin for treating stroke (1991) Canadian patent application, 910211.
85. Bebin, M. and Bleck, T.P. (1994) New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 48, 153-171.
86. Patsaloa, P.N. and Duncan, J.S. (1994) A review of their current status and clinical potential. CNS Drugs 2, 40-77.
87. Uthman, B.M. and Wilder, B. J. (1989) Emergency management of seizures: An overview. Epilepsia 30, S33-S37.
88. Bleck, T.P. (1993) Advances in the management of refractory status epilepticus. Crit. Care Med. 21, 955-957.
89. Cascino, G.D. (1994) Contemporary perspectives on evaluation and treatment. May Clin. Proc. 69, 1199-1211.
90. Jagoda, A. and Riggio, S. (1993) Refractory status epilepticus in adults. Ann. Emerg. Med. 22, 1337-1348.
91. Shek, E. (1994) Chemical delivery systems and pro-drugs of anticonvulsive drugs. Adv. Drug Deliv. Rev. 14, 227-241.
92. Wilder, B.J. (1994) How about the new antiepileptic drugs? Can. J. Neurol. Sci. 21, S17-S41.
93. Anon. (1989) Comparison of fosphenytoin and phenytoin. Drugs Future 14, 611-613.
94. Anon. (1990) ACC-9653, fosphenytoin sodium. Drugs Future 15, 720-721.
95. Scholtes, F.B., Renier, W.O. and Meinardi, H. (1993) Generalized convulsive status epilepticus: Pathophysiology and treatment. Pharm. World. Sci. 15, 17-28.
96. Fisher, R.S. (1993) Emerging antiepileptic drugs. Neurology 43, S12-S20.
97. Kuhl, D.A., Boucher, B.A. and Muhlbauer, M.S. (1990) Prophylaxis of posttraumatic seizures. DICP Ann. Pharmacother. 24, 277-285.
98. Ramsay, R.E. (1993) Treatment of status epilepticus. Epilepsia 34, S71-S81.
99. Starr, C. (1993) Antiepileptic drugs: New hope on horizon. Drug Top. 173, 30-39.
100. Dupuis, R.E. and Miranda-Massari, J. (1991) Anticonvulsants: Pharmacotherapeutic issues in the critically ill patient. AACN Clin. Issues Crit. Care Nurs. 2, 639-656.
101. Wilder, B.J. McLean, J.R. and Uthman, B.M. (1993) Phenytoin. In: Wyllie, E., (Ed.) The treatment of epilepsy: Principles and practice. Lea & Febiger, Malvern, PA, pp. 887-899.
102. Anon. (1992) Fosphenytoin sodium. ACC-9653. Anticonvulsant. Drugs Future 17, 624.
103. Browne, T.R. (1990) The pharmacokinetics of agents used to treat status epilepticus. Neurology 40, 28-32.
104. Wilder, B.J., Campbell, K., Uthman, B.M., Hargrove, S. and Barber, C. (1992) Safety, efficacy and pharmacokinetics of fosphenytoin, a phenytoin prodrug. Epilepsia 33, 117.
105. Wilder, B.J., Ramsay, E., Marriott, J., Loewen, G. and Smith, H. (1993) Safety and tolerance of intramuscular administration of fosphenytoin, a phenytoin prodrug, for 5 days in patients with epilepsy. Neurology 43, A308 (Abstr. 582P).
106. Boucher, B.A., Bombassaro, A.M., Watridge, C.B., Achari, R. and Turlapaty, P. (1988) Phenytoin prodrug safety, tolerability and pharmacokinetics in patients following IV and IM administration, Pharmacotherapy 8, 133-134.
107. Andrews, C.O., Turnbull, T.L., Paloucek, F.P., Delacruz, F.G., Fischer, P.A. and Fischer, J.H. (1994) Safety and pharmacokinetics of fosphenytoin following intravenous loading dose administration. Pharmacotherapy 14, 367 (Ahstr. 136).
108. Legarda, S., Maria, B.L., Matsuo, F., Allen, F.H. Jr., Runge, J.W., Kugler, A.R. and Marriott, J. (1993) Safety, tolerance, and pharmacokinetics of fosphenytoin, a phenytoin prodrug, in status epilepticus. Epilepsia 34, 60.
109. Allen, F.H.J., Runge, J.W., Legarda, S., Maria, B.L., Matsuo, F., Kugler, A.R. and Knapp, L.E. (1995) Multicenter, open-label study on safety, tolerance, and pharmacokinetics of intravenous fosphenytoin (Cerebyx) in status epilepticus. Epilepsia 35, 93.
110. Wilder, B.J., Slater, J., Malone, J, Campbell, K., Gilmore, R., Uthman, B.M.., Perchalski, R.J. and Ramsay, R.E. (1993) Parenteral loading and maintenance of phenytoin with fosphenytoin, a phenytoin prodrug. Epilepsia 34, 27.
111. Jones, M.A., Kramer, R.E., Levisohn, P.M., Shimoda, L., Kugler, A.R. and Knapp, L.E. (1994) Pharmacokinetics and safety of intravenous fosphenytoin (Cerebyx) in neurosurgical patients. Epilepsia 35, 161.
112. Dean, J.C., Smith, K.R. Jr., Boucher, B.A., Michie, D.D., Kulger, A. and Marriott, J. (1993) Safety, tolerance, and pharmacokinelics of intramuscular fosphenytoin, a phenytoin prodrug in neurosurgery patients. Epilepsia 34, 111.
113. Hartman, D., Hartman, J., Stampfli, H., Quon, C. and Maher, R. (1987) Cardiovascular effects of ACC-9653, a prodrug of phentyoin, administered by intravenous injection in anesthetized dogs. Fed. Proc. 46, 708 (Abstr. 2293).
114. Jamerson, B.D., Dukes, G.E., Brouwer, K.L.R., Donn, K.H., Messenheimer, J.A. and Powell, J.R. (1994) Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy 14, 47-52.
115. Marriott, J.G., Levoy, R.F., Murray, J. and Smith, H. (1993) Injection site reaction following intramuscular administration of fosphenytoin versus placebo. Can J. Neurol. Sci. 20, S179 (Abstr. 6-11-05).